Martin Schou Pedersen

Copenhagen University Hospital
Country flagDenmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Objectives An Escherichia coli isolate, WGS1363, showed resistance to piperacillin/tazobactam but susceptibility to cephalosporins and contained a previously unrecognized β-lactamase, CTX-M-255, as the only acquired β-lactamase. CTX-M-255 was identical to CTX-M-27 except for a G239S substitution. Here, we characterize the hydrolytic spectrum of CTX-M-255 and a previously reported β-lactamase, CTX-M-178, also containing a G239S substitution and compare it to their respective parental enzymes, CTX-M-27 and CTX-M-15. Methods All β-lactamase genes were expressed in E. coli TOP10 and MICs to representative β-lactam-antibiotics were determined. Furthermore, blaCTX-M-15, blaCTX-M-27, blaCTX-M-178 and blaCTX-M-255 with C-terminal His-tag fusions were affinity purified for enzyme kinetic assays determining Michaelis–Menten kinetic parameters against representative β-lactam-antibiotics and IC50s of clavulanate, sulbactam, tazobactam and avibactam. Results TOP10-transformants expressing blaCTX-M-178 and blaCTX-M-255 showed resistance to penicillin/β-lactamase combinations and susceptibility to cephalothin and cefotaxime in contrast to transformants expressing blaCTX-M-15 and blaCTX-M-27. Determination of enzyme kinetic parameters showed that CTX-M-178 and CTX-M-255 both lacked hydrolytic activity against cephalosporins and showed impaired hydrolytic efficiency against penicillin antibiotics compared to their parental enzymes. Both enzymes appeared more active against piperacillin compared to benzylpenicillin and ampicillin. Compared to their parental enzymes, IC50s of β-lactamase-inhibitors were increased more than 1000-fold for CTX-M-178 and CTX-M-255. Conclusions CTX-M-178 and CTX-M-255, both containing a G239S substitution, conferred resistance to piperacillin/tazobactam and may be characterized as inhibitor-resistant CTX-M β-lactamases. Inhibitor resistance was accompanied by loss of activity against cephalosporins and monobactams. These findings add to the necessary knowledge base for predicting antibiotic susceptibility from genotypic data.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (21)

Ulrik Fahnøe

Københavns Universitet

DENMARK
View details

Lotte Jelsbak

Associate Professor at Roskilde University

Roskilde University

DENMARK
View details

Jenny Dahl Knudsen

Head of department, MD,Dr.M.Sci

Rigshospitalet

DENMARK
View details

Mads Albertsen

Aalborg University

DENMARK
View details

Rasmus L. Marvig

Associate Professor

Technical University of Denmark

DENMARK
View details

Omid Rezahosseini

University of Copenhagen

DENMARK
View details

Håvard Jenssen

Professor

University of Oslo

NORWAY
View details

Christian Johann Lerche

Assistant Lecturer

Københavns Universitet

DENMARK
View details

Sarah Mollerup

Copenhagen University Hospital

DENMARK
View details

Maarten van Wijhe

Roskilde University

DENMARK
View details

Pernille Ravn

MD, PhD, Associate Professor, Senior Consultant

Copenhagen University Hospital

DENMARK
View details

Uffe Vest Schneider

Section Head and Chief Physician

Statens Serum Institut

DENMARK
View details

Zitta Barrella Harboe

University of Copenhagen

DENMARK
View details

Birgitte Lindegaard

-

DENMARK
View details

Troels Lillebaek

Københavns Universitet

DENMARK
View details

Thomas Yssing Michaelsen

Aalborg University

DENMARK
View details

Kai Blin

Technical University of Denmark

DENMARK
View details

Mads Frederik Eiberg

University of Copenhagen

DENMARK
View details

Amanda Bolt Botnen

Statens Serum Institut

DENMARK
View details

Andrea Galli

Københavns Universitet

DENMARK
View details

Kristian Schønning

Copenhagen University Hospital

DENMARK
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.